Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence

Natali, Andrea; Nesti, Lorenzo; Tricò, Domenico; Ferrannini, Ele

doi:10.1186/s12933-021-01385-5

Cardiovascular Diabetology

Table 1 Clinical studies on the effects of the therapy with GLP-1Ra on left ventricular function and structure in patients with T2D

From: Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence

Study	Design	Exposure, duration	Outcome, method	Population, n	Baseline	Change (%)	p
Systolic parameters
[23]	Prospective vs. placebo	Liraglutide 1.8 μg/die for 26 weeks	LVEF, CMRI	NoHF, 23 vs. 26	55%	− 1%	0.002
[28]	Prospective vs. placebo	Albiglutide various dosage, 12 weeks	LVEF, US	HFrEF, 29 vs. 30	32%	− 2%	ns
[22]	Single arm, prospective	Liraglutide 0.9 μg/die for 26 weeks	LVEF, US	HFpEF, 31	NA	NA	ns
[24]	Prospective vs. aCTRL	Liraglutide 1.8 μg/die vs. metformin 2 g for 6 months	GLS’, US	NoHF, 30 vs. 30	15%	+ 1.2	0.043
[25]	Prospective vs. aCTRL	Liraglutide 1.8 mg, or glimepiride 4 mg for 18 weeks	LVEF, US	NoHF with subclinical dysf, 33 vs. 29	53%	− 2.1	ns
			GLS, US		15%	0	ns
[26]	Prospective vs. aCTRL	Liraglutide 1.8 mg, or glimepiride 4 mg for 25 weeks	LVEF, US	HFrEF, 146 vs. 156	25	+ 1.1	ns
[27]	Prospective vs. placebo	Liraglutide 1.8 mg for 24 weeks	LVEF, US	HFrEF, 122 vs. 119	33%	− 0.7	ns
			GLS, US		11%	0.6	ns
Diastolic parameters
[23]	Prospective vs. placebo	Liraglutide 1.8 μg/die for 26 weeks	E/e′, CMRI	NoHF, 23 vs. 26	7.3	− 0.9	0.001
[22]	Single arm, prospective	Liraglutide 0.9 μg/die for 26 weeks	E/e′, US	HFpEF, 31	12.7	− 2.7	0.0371
[24]	Prospective vs. aCTRL	Liraglutide 1.8 μg/die vs. metformin 2 g for 6 months	E/A, US	NoHF, 30 vs. 30	0.92	+ 0.6	ns
[25]	Prospective vs. aCTRL	Liraglutide 1.8 mg, or glimepiride 4 mg for 18 weeks	E/e′, US	NoHF, 33 vs. 29	12.5	− 0.5	ns
[27]	Prospective vs. placebo	Liraglutide 1.8 mg for 24 weeks	LVEF, US	HFrEF, 122 vs. 119	12.6	− 0.6	0.03
Remodeling
[28]	Prospective vs. placebo	Albiglutide various dosage, 12 weeks	LVDV, US	HFrEF, 29 vs. 30	196	− 0.2%	ns
			LVMi, US
[23]	Prospective vs. placebo	Liraglutide 1.8 μg/die for 26 weeks	LVEDV, CMRI	NoHF, 23 vs. 26	147	− 11	0.002
			LVMi, CMRI		49	− 1.5	ns
[26]	Prospective vs. aCTRL	Liraglutide 1.8 mg, or placebo 4 mg for 25 weeks	LVEFVi, US	HFrEF, 146 vs. 156	140	+ 6.7	ns
[27]	Prospective vs. placebo	Liraglutide 1.8 mg for 24 weeks	LVEDV, US	HFrEF, 122 vs. 119	163	− 4	ns

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com